Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Immunogenicity of CBL8851 (A82/B86) in Healthy Adults
NCT06360250Phase 1Not yet recruiting
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of CBL8851 in Tetanus (3 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Safety evaluation index at 12 months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
CBL8851
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT06360250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360250.